QuantRx, Mass General to develop PET agents for Alzheimer?s
QuantRx’s molecular imaging company, FluoroPharma, which develops cardiovascular molecular imaging agents for the PET market, has entered into a license agreement with Massachusetts General Hospital (MGH) for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease (AD).
The licensed technologies, co-developed by FluoroPharma and MGH scientists, target multiple biological processes associated with Alzheimer's disease.
Currently, there is no single diagnostic test that proves a person has Alzheimer's, according to QuantRx.
"Our molecular imaging approach to treating AD includes multiple molecular compositions that target AD associated phenomena - low acetylcholine and amyloid plaque formation. With some agents, it may be possible to improve brain function by inhibiting the breakdown of acetylcholine, and with others we may be able to prevent the formation of amyloid plaque by inhibiting protein misfolding," explained David Elmaleh, MD, FluoroPharma's chairman and scientific founder.
The licensed technologies, co-developed by FluoroPharma and MGH scientists, target multiple biological processes associated with Alzheimer's disease.
Currently, there is no single diagnostic test that proves a person has Alzheimer's, according to QuantRx.
"Our molecular imaging approach to treating AD includes multiple molecular compositions that target AD associated phenomena - low acetylcholine and amyloid plaque formation. With some agents, it may be possible to improve brain function by inhibiting the breakdown of acetylcholine, and with others we may be able to prevent the formation of amyloid plaque by inhibiting protein misfolding," explained David Elmaleh, MD, FluoroPharma's chairman and scientific founder.